Help

BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

Drugmaker to settle US charity probe for $52.6 million

Reprints
Drugmaker to settle US charity probe for $52.6 million

(Reuters) — Danish drugmaker Lundbeck said on Wednesday that it will pay $52.6 million to resolve a U.S. probe into its financial support of patient assistance charitable foundations.

The company, formally called H. Lundbeck A/S, said it had reached an agreement with the U.S. Justice Department, which has investigating drugmakers’ support of charities that help Medicare patients cover out-of-pocket drug costs.

Lundbeck, which develops and distributes drugs for neurological and psychological diseases such as depression and Alzheimer’s, said the settlement would include no admission of wrongdoing and is subject to further negotiation.

Drug companies are prohibited from subsidizing copayments for patients enrolled in the Medicare government health care program for the elderly. But companies may donate to nonprofits providing copay assistance as long as they are independent.

The U.S. Attorney’s Office in Massachusetts has been leading the industrywide investigation. A spokeswoman for the office declined to comment.

The probe most recently resulted in Pfizer Inc. on May 25 agreeing to pay $23.85 million to resolve claims that it used a purportedly independent charity as a conduit to pay illegal kickbacks to Medicare patients.

In December, United Therapeutics Corp. reached a $210 million settlement to resolve similar allegations it improperly used a charity to cover copayments.

Jazz Pharmaceuticals P.L.C. announced on May 8 that it had reached an agreement to pay $57 million to resolve a related investigation.

 

 

 

Read Next

  • Insurance cover for directors and officers "woefully inadequate"

    Andrew Watson, head of class action practice at Australian law firm Maurice Blackburn Pty. Ltd., said that the insurance taken out by listed companies for directors and senior officers is "woefully inadequate" and the firms should be forced to take out a minimum level of cover, Financial Review reported. Mr. Watson said that all listed companies should be required to have a minimum of $50 million Australia ($40 million) D&O cover. Companies listed on the ASX200 Australian Securities Exchange need to have a minimum of AUD 100 million cover and those listed on the ASX100 AUD 150 million, he added.